Evaxion A (EVAX) Other Accumulated Expenses (2020 - 2025)
Evaxion A's (EVAX) quarterly Other Accumulated Expenses came in at $1.2 million in Q2 2025, up 56.5% YoY from $738000.0 in Q2 2024, and up 24.6% on a QoQ basis from $927000.0 in Q4 2024.
Evaxion A (EVAX) Other Accumulated Expenses (2020 - 2025) Analysis & Trends
Evaxion A (EVAX) has 6 years of Other Accumulated Expenses data on file, last reported at $1.2 million in Q2 2025.
- Quarterly Other Accumulated Expenses rose 56.5% year-over-year to $1.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.2 million (up 56.5% YoY) and the FY2024 annual result came in at $927000.0, down 7.85% from the prior year.
- Other Accumulated Expenses advanced to $1.2 million in Q2 2025, from $927000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q2 2021 to a low of $665000.0 in Q4 2022.
- A 5-year average of $1.4 million and a median of $1.0 million in 2021 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses slumped 70.86% — and 2023, when it surged 60.02%.
- Tracing EVAX's Other Accumulated Expenses over 5 years: stood at $1.0 million in 2021, then sank by 35.75% to $665000.0 in 2022, then soared by 51.28% to $1.0 million in 2023, then declined by 7.85% to $927000.0 in 2024, then grew by 24.6% to $1.2 million in 2025.
- The last three Other Accumulated Expenses figures came in at $1.2 million (Q2 2025), $927000.0 (Q4 2024), and $738000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.16 Mn |
| Dec 31, 2024 | 927,000.00 |
| Jun 30, 2024 | 738,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Jun 30, 2023 | 1.49 Mn |
| Dec 31, 2022 | 665,000.00 |
| Jun 30, 2022 | 933,000.00 |
| Mar 31, 2022 | 744,000.00 |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 2.91 Mn |
| Jun 30, 2021 | 3.11 Mn |
| Mar 31, 2021 | 2.55 Mn |
| Dec 31, 2020 | 2.26 Mn |